Veradermics, Inc
MANE · Healthcare · $82.1M mkt cap · FY2025 filings · Not rated ·
Not rated
We don't have enough comparable filing data to score at least four of the five filters for MANE, so we don't publish a composite. Missing: businessTrend, pricingPower, returnsOnCapital, capitalDiscipline. No composite: 4 components abstained (businessTrend: Fewer than two aligned fiscal years of revenue and diluted EPS are available; the filing history does not contain a measurable trend.; pricingPower: Not enough years of gross-margin data to score pricing power.; returnsOnCapital: Not enough years of ROIC data to score returns on capital.; capitalDiscipline: Not enough owner-earnings history to score capital discipline.).
3 years of fundamentals
The business, in plain English
MANE's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not disclosed in MANE’s filings for these years — we don’t estimate it.
Not disclosed in MANE’s filings for these years — we don’t estimate it.
Not disclosed in MANE’s filings for these years — we don’t estimate it.
Not disclosed in MANE’s filings for these years — we don’t estimate it.
Gaps in a line mean that item isn’t in MANE’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
No composite readings yet — MANE’s filings don’t give the engine enough comparable data to score, and we log that honestly instead of guessing a number.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Healthcare context
Not ranked — MANE doesn’t have enough comparable filing data for a composite score, so we don’t place it on the board.
Healthcare leaders by Moat Score
- #1IDXX IDEXX LABORATORIES INC /DE96.2 out of 100, Wide moatWide moat
- #2LLY ELI LILLY & Co94.3 out of 100, Wide moatWide moat
- #3GRMN GARMIN LTD93.8 out of 100, Wide moatWide moat
Common questions about MANE
- Does Veradermics, Inc have an economic moat?
- We don't publish a Moat Score for Veradermics, Inc (MANE): its SEC filings don't provide enough comparable data to score at least four of the five filters, and the Index records each gap rather than a guessed number. Missing inputs: revenue and EPS trend, pricing power, returns on capital, capital discipline.
- How has MANE's Moat Score changed over time?
- The record logs 12 readings since Jul 18, 2026, none with a composite — MANE hasn't had enough comparable filing data to score. No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.